Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ascendis Pharma A (ASND) over the last 8 years, with Q3 2025 value amounting to $381.7 million.

  • Ascendis Pharma A's Other Accumulated Expenses rose 4011.06% to $381.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $381.7 million, marking a year-over-year increase of 4011.06%. This contributed to the annual value of $323.6 million for FY2024, which is 6159.85% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Other Accumulated Expenses is $381.7 million, which was up 4011.06% from $373.9 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Other Accumulated Expenses high stood at $381.7 million for Q3 2025, and its period low was $13.6 million during Q1 2021.
  • Over the past 4 years, Ascendis Pharma A's median Other Accumulated Expenses value was $272.4 million (recorded in 2024), while the average stood at $215.0 million.
  • The largest annual percentage gain for Ascendis Pharma A's Other Accumulated Expenses in the last 5 years was 6713.17% (2021), contrasted with its biggest fall of 2552.43% (2021).
  • Quarter analysis of 4 years shows Ascendis Pharma A's Other Accumulated Expenses stood at $38.2 million in 2021, then skyrocketed by 424.71% to $200.3 million in 2023, then surged by 59.55% to $319.5 million in 2024, then rose by 19.46% to $381.7 million in 2025.
  • Its Other Accumulated Expenses stands at $381.7 million for Q3 2025, versus $373.9 million for Q2 2025 and $274.9 million for Q1 2025.